Phase 1Completed
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
A Phase 1 Study to Evaluate the Drug-Drug Interaction Between ABBV-CLS-7262, Rosuvastatin, and Digoxin Following Multiple Doses of ABBV-CLS-7262
- Sponsor
- Calico Life Sciences LLC (Industry)
- Enrolment
- 12 enrolled
- Conditions
- Healthy
- Interventions
- ABBV-CLS-7262
- Ages
- adults, older adults
- Registry
- NCT05763459
From the registry
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
Primary outcomes
- Pharmacokinetics of Rosuvastatin
- Pharmacokinetics of Digoxin